Diabetes prevalence is increasing above and beyond what can be attributed to population growth as reduced physical activity and increased sugar in people's diets is leading to an epidemic that is pushing healthcare systems to breaking point. While therapeutic treatments remain limited for diabetes patients, measurement and management of their glycemic status can prove beneficial. Glucose and HbA1C are currently utilised to manage diabetes in the short and long term respectively. However, problems with the accuracy of the HbA1c in certain diabetes patients, particularly those with renal problems and/or anaemia make it not ideal in all situations. Additionally its half life of 2-3 months make it slow to respond to glycemic changes.
Measurement of human serum albumin may be beneficial in both filling the gap between glucose and HbA1c and being less susceptible to interferents. HSA has a half life of between 2-3 weeks and like haemoglobin is readily glycated. Any changes in glycated HSA will demonstrate changes in a patient's glycemic status over the preceding weeks instead of months like HbA1c. Additionally it has been demonstrated to be a better representation of glucose levels in certain patient groups.
The relative lack of GHSA testing in the clinic comes down to the cost, complexity and lack of specificity of current techniques. A simple test is needed which can determine the GHSA/HSA ratio of a patient more accurately then current techniques while at a cost that is viable for restrained healthcare budgets.
Within this thesis the selection and subsequent testing of aptamers to HSA and early stage glycated HSA (GHSA) is demonstrated.